RYVU THERAPEUTICS ZY-,40/ PLSELVT00013 /
| 2024-11-15 7:31:22 PM | Chg. -0.420 | Volume | Bid8:03:44 PM | Ask8:03:44 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 10.000EUR | -4.03% | 0 Turnover: 0.000 |
-Bid Size: - | -Ask Size: - | 243.13 mill.EUR | - | - |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | -4.00 PLN | -13.04% |
| EPS Diluted: | - PLN | -13.04% |
| Revenues per Share: | 2.91 PLN | -21.93% |
| Book Value per Share: | 11.23 PLN | -39.98% |
| Cash Flow per Share: | -3.66 PLN | - |
| Dividend per Share: | - PLN | - |
| Total | in th. | |
| Revenues: | 67,296.00 PLN | -1.67% |
| Net Income: | -92,112.00 PLN | 9.94% |
| Operating Cash Flow: | -84,550.00 PLN | - |
| Cash and Cash Equivalents: | 57,939.00 PLN | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | 15.60 | 19.75 |
| P/BV ratio: | 4.04 | 5.12 |
| P/CF Ratio: | -12.41 | -15.72 |
| PEG: | 0.87 | - |
| Earnings Yield: | -8.81% | -6.96% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 243.13 mill. EUR | 306.04 mill. EUR |
| Free Float Market Cap.: | - EUR | - EUR |
| Market Cap. / Employee: | - EUR | - EUR |
| Shares Outstanding: | 23.12 mill. | |
Profitability
| Gross Profit Margin: | - |
| EBIT Margin: | -150.01% |
| Net Profit Margin: | -136.88% |
| Return on Equity: | -35.48% |
| Return on Assets: | -22.85% |
Financial Strength
| Liquidity I / Cash Ratio: | 83.12% |
| Liquidity II / Quick Ratio: | 130.23% |
| Liquidity III / Current Ratio: | 399.40% |
| Debt / Equity Ratio: | 55.32% |
| Dynam. Debt / Equity Ratio: | -169.85% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - PLN |
| Revenues / Employee: | - PLN |
| Net Income / Employee: | - PLN |
| Total Assets / Employee: | - PLN |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | IFRS |
| Currency: | PLN |
